Adipotide, also known as FTPP or Prohibitin-targeting peptide, is a synthetic peptide compound designed to target and reduce adipose tissue. It is composed of a homing domain that targets prohibitin, a protein found on the surface of adipose vasculature, and a pro-apoptotic domain that induces cell death. The synthesis of Adipotide involves standard peptide synthesis techniques, typically using solid-phase peptide synthesis (SPPS) methods. Researchers have primarily investigated Adipotide in the context of metabolic disorders, particularly obesity. Studies in animal models have shown that Adipotide can lead to significant weight loss by reducing fat tissue mass. The compound has also been explored for its potential effects on improving insulin sensitivity and reducing obesity-related complications. The mechanism of action of Adipotide involves targeting the blood vessels supplying adipose tissue. By binding to prohibitin on the surface of these cells, Adipotide disrupts the blood supply, leading to apoptosis of the fat cells. This targeted approach helps in reducing adipose tissue without affecting other tissues. Pharmacokinetic studies of Adipotide have shown that it has a relatively short half-life, with rapid clearance from the bloodstream. The bioavailability of Adipotide varies depending on the route of administration, with subcutaneous and intravenous routes being the most studied. Current research on Adipotide is primarily in preclinical stages, with ongoing studies to better understand its efficacy and safety profile. Regulatory agencies have not yet approved Adipotide for clinical use, and it remains a compound of interest in the research community for its potential therapeutic applications in obesity management.